Akili to operate as wholly owned subsidiary of Virtual TherapeuticsBOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Aki...
Akili to operate as wholly owned subsidiary of Virtual TherapeuticsKIRKLAND, Wash. & BOSTON--(BUSINESS WIRE)--Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games, and Akili, Inc. (Nasdaq: AKLI), ...
Shionogi amendment provides Akili with near-term cash payments and cancellation of debt obligation Company announces exploration of strategic alternatives and associated workforce reduction Company to release first quarter 2024 financial results on Ma...
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare.
Japanese Product Now Under Review for Nationwide Marketing ApprovalBOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital ...
Akili, Inc., the leading digital medicine company behind EndeavorOTC™, today released results from a new study examining the ways in which ADHD impacts the U.S. workforce.
Akili, Inc., a leading digital medicine company, today announced that Eddie Martucci transitioned to the role of Board chair, and Matt Franklin has been appointed to serve as president and CEO of the company and as a member of its board of directors.
Clinical trial data show that 83% of adults with ADHD experienced improved focus, and 73% reported improvement in quality of life after EndeavorOTC treatment Available nationwide without a prescription, EndeavorOTC users can now access their personali...
Non-prescription model will increase patient access to clinically-validated non-drug treatments and reduce Akili’s reliance on intermediaries Continued growth in consumer demand and engagement for EndeavorOTC™ during its initial three months on the ma...
EndeavorRxⓇ prescriptions in pediatric ADHD market grew 27% in Q2 2023 over Q1 2023 Company is preparing FDA submission for EndeavorOTCTM as over-the-counter treatment, following its June 2023 product release in the adult ADHD market Company reaffirms...